Trillium Therapeutics Inc
Sector: Manufacturing
Industry: Biological Product (except Diagnostic) Manufacturing
17.81
0.08
(0.451%)
Volume:
1,049,891
52 week range:
5.8 - 20.96
Market Cap:
1.867B
Company Description:
Trillium is an immuno-oncology company developing innovative therapies for the treatment of cancer. The company’s two clinical programs, TTI-621 and TTI-622, target CD47, a “don’t eat me” signal that cancer cells frequently use to evade the immune system.